Skip To Main Content
Michael Flanagan on Muck Rack

Michael Flanagan

Verified
Chicago
As seen in: FirstWord Pharma, Daily Mail, Irish Daily Mail, Newsweek, Chicago Tribune, Chicago Tribune Opinion, MDPI, The Hill, Chicago Sun-Times, JAMA Oncology, Townhall and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Michael

Contact Michael, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Two Hospitalized After Personal Watercraft Collision Near Key Biscayne

|
By Michael Flanagan Verified
| florida-justice.com
Two men were hospitalized Thursday afternoon after a collision involving two personal watercraft near Key Biscayne, according to Miami Fire Rescue. The crash occurred in the waters near the Rickenbacker Causeway, prompting an emergency marine response. Both men were transported to a local trauma center with injuries and are expected to survive. Authorities are investigating what led to the collision.
Open in Who Shared Issue with article?

KOL Views Preview: Will tolerability weigh on prospects for Boehringer, Zealand's survodutide in metabolic arena?

|
By Michael Flanagan Verified
| FirstWord Pharma Verified
Detailed Phase III findings unveiled at the American Diabetes Association's (ADA) annual meeting confirm that survodutide can achieve competitive weight loss in obese patients with or without metabolic dysfunction-associated steatotic liver disease (MASLD).
Open in Who Shared Issue with article?

KOL Views Preview: Is GSK's bepirovirsen readout a watershed moment for HBV?

|
By Michael Flanagan Verified
| FirstWord Pharma Verified
Chronic hepatitis B virus (HBV) infection has been an exceedingly tough nut to crack but detailed data from the Phase III B-Well trials suggest that GSK's bepirovirsen, a multimodal antisense oligonucleotide licensed from Ionis Pharmaceuticals, has made a breakthrough by achieving a functional cure rate of nearly 20%.
Open in Who Shared Issue with article?
See all 132 licensed articles (147 Total)